Previously, our group demonstrated that systemic expression of IL-12+IL-18 was capable of inducing a strong antitumor effect against 2 different tumor cells lines in vivo (B16, melanoma and 3LL, lung carcinoma). The gene discussed is IL18; the disease is melanoma.